Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award

SUNNYVALE, Calif., Feb. 25, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its Senior Vice President, General Counsel and Corporate Secretary, Darren Milliken, was named "Best General Counsel, Small Public Company" by the Silicon Valley/San Jose Business Journal and the San Francisco Business Times as part of their 'Best Bay Area Corporate Counsel Awards'. This annual awards program honors the dedicated in-house lawyers who keep the business world running but who rarely receive public recognition.

Upon joining Accuray in 2004, Milliken leveraged his physics background to develop a deep understanding of the CyberKnife® Robotic Radiosurgery System and through that has provided an incredible level of insight in guiding the Company from a small privately-held company to a global, public entity. As the first attorney hired at Accuray, Milliken's many accomplishments include leading Accuray through its IPO; overseeing the Company's expansion from six U.S. patents held to over 66 with 100 more filed internationally; and participating as an instrumental leader in the Company's strategic alliance with Siemens Healthcare.

"We are thrilled to see Darren recognized by our local business community as a thought leader in corporate law and governance.  At Accuray, we want the highest legal and ethical standards to guide us in everything we do, and Darren's expertise and strategic guidance have been invaluable as we have grown into a global leader in radiosurgery," said Euan S. Thomson, Ph.D., president and CEO of Accuray.

"I am very honored to have been selected for an award of this caliber. Being a part of the Accuray team has given me the unique opportunity to work not only as an attorney, but also a business leader," said Milliken. "My success is in large part attributable to the support and success of my talented colleagues here at Accuray, to whom I want to express my gratitude. I look forward to continuing our collaboration toward delivering best-in-class innovations to help patients across the globe."

The Silicon Valley/San Jose Business Journal's 'Best Bay Area Corporate Counsel Awards' recognized 26 leaders in the local business community this year. Among the categories honored are Best General Counsel for a Public Company, Best General Counsel for a Private Company, Best IP Lawyer, Community Champion Winner, and Lifetime Achievement. The winners and finalists were selected by an independent panel of judges and an awards ceremony was held on February 22, 2011 at the San Francisco Marriott to recognize the recipients.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 222 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com. 

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to management experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, clinical results and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on January 27, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated